Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 4Sarcoma 2Plasma cell 2Other hematologic neoplasm 2Lymphoid 2Dermatologic 2Tumor-Agnostic 1Gynecologic 1CNS 1

Conditions

Melanoma 1Brain Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 73Temozolomide 68Specimen Handling 48Radiotherapy 40Radiosurgery 29Bevacizumab 26Radiation 25Cyclophosphamide 25Nivolumab 21Biopsy 21pembrolizumab 20Carboplatin 16X-Rays 14Lomustine 13Ipilimumab 13fludarabine 12Irinotecan 12Vincristine 11Topotecan 11Surgical Procedures, Operative 11Cisplatin 11Blood Specimen Collection 11trametinib 9dinutuximab 9Immunoglobulin G 8Etoposide 8Doxorubicin 8lutetium Lu 177 dotatate 7fludarabine phosphate 7atezolizumab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
cobimetinib × CNS × 90 days × Clear all
NCT03175432 2026-04-15

Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
29 enrolled
CNSDermatologic

Brain Neoplasms, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡